Stoke Therapeutics, Inc. (STOK)
收市後：
| 前收市價 | 11.66 |
| 開市 | 11.41 |
| 買盤 | 11.59 x 100 |
| 賣出價 | 11.72 x 400 |
| 今日波幅 | 11.11 - 11.82 |
| 52 週波幅 | 3.35 - 16.40 |
| 成交量 | |
| 平均成交量 | 1,215,509 |
| 市值 | 609.254M |
| Beta 值 (5 年，每月) | 0.76 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.38 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 23.67 |
ZacksEarnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksStoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
BenzingaStoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
Monday, Stoke Therapeutics Inc (NASDAQ:STOK) released new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged, and refractory seizures. Data showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements i
